TEVA PHARMACEUTICALS By: Kaity Brown
About Teva Established in Became TEVA pharmaceuticals in the 1930s Currently their headquarters is in Israel and are active in 60 countries. Aim is to produce drugs in specialty areas such as CNS, Respiratory, Women’s Health, Oncology, and Biologicals as well as be a major generic manufacturer. Income is 1.96 billion. Have billion in sales, and a debt/Equity ratio of 0.65
Products CNS and Pain Products: AZILECT [Parkinson’s] NUVIGIL [Sleep Disorders] Respiratory Products PROAIR HFA Estimated 1.5 million prescriptions are filled daily in US with their generic products
January 24, 2013 January 23: Releases reports from the second Phase III Trial for Nuvigil to be used with major depression associated with bipolar disorder came back negative. Stock Range: $37.24-$38.22
January 31, 2013 January 31: Announced termination of their collaboration with CureTech which is a company that worked with a monoclonal antibody for treating tumors and malignancies. Stock Range: $37.35-$38.15
February 7, 2013 February 2: enrolled 1 st patient into a phase 4 trial for Azilect for the treatment of mild cognitive impairment in Parkinson’s disease with plans for it to be the largest ever. Currently used as an initial treatment for Parkinson’s. February 7: Released 2012 financial report 4 th Quarter net revenue: $5.2 billion, $2.6 billion from US which was a 14% decrease from Full Year net revenue: $20.3 billion. 15% increase in quarterly dividend. Found that specialty drugs are higher than generic sales in US and both have declined since Shares have decreased 15% over past year. Stock Range: $37-$38.16
February 21, 2013 February 19: Seeking Alpha wrote an article mentioning Teva as stocks that will be promising for improvement and a company to watch for for February 14: FDA approves the ANDA for Teva’s new generic Adderall XR. Stock Range: $37.96-$38.96
February 28, 2013 February 22: Announced they will present data for the improvement of sleep quality and relief with QNASL at Annual Allergy Meeting February 25: Featured Healthcare Laggard because stocks fell.50, or 1.9% over the day Stock Range: $37.23-$38.45
March 7, 2013 March 6: Enrolled 1 st patient in phase III trials for Concerto for RRMS. Goal is to improve disability progression. March 1: Called for redemption on approximately $500 million in outstanding principal amount of 5.55% Senior Notes. Stock Range: $37.11-$39.63 Lowest point fell on March 1 st.
March 21, 2013 March 13: Announced that they and Band Against MS, a foundation formed by country music singer Clay Walker, have joined together for the “Stick With It!” campaign. Purpose is to educate patients with RRMS about the importance of adherence for long term management March 14: Will pay $2.25 million for environmental penalties including leaking a fluorescent green discharge into a Missouri River. March 14: Released information of studies on AZILECT, COPAXONE, and ALLEGRO and announced to present it at the American Academy of Neurology annual meeting Stock Range: $40-$41.50
March 28, 2013 March 27: Considered to be one of 4 that is dragging the drug industry down March 28: Released 14 to 10 experts say hold instead of buy. Given a ratings score of C+ Positives: good cash flow and solid financial position Negatives: deteriorating net income, disspointing equity return, and bad stock performance Stock Range: $39.32-$40.29
April 4, 2013 March 29: FDA approves NDA for Quartette birth control. April 1: The Motley Fool posted a video about if Teva stock is still worth owning? Reported yes because of dividend increases, small amount of debt, and the promising sale increase with ObamaCare Stock Range: $39.25-$39.86
Buy, Sell, or Hold? As of now, stocks are at about $39.45/share Rating 5 out of 10 Current recommendation is to Hold any stocks owned or sell. No significant growth in stock value despite a sales growth of 10.9% Income growth = -28.9% No new exciting drugs seem to be in the pipeline. Sources: MSN Money and TevaPharm.com